J. Goldman & Co’s Cytokinetics CYTK Stock Holding History

J. Goldman & Co’s Portfolio CYTK Stock Details CYTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.53M	Buy	18,002 +5,995	+50%	+$430K	0.04%	392
2026 Q1	$791K	Sell	12,007 -5,638	-32%	-$358K	0.02%	451
2025 Q4	$1.12M	Buy	17,645 +3,140	+22%	+$195K	0.03%	372
2025 Q3	$797K	Sell	14,505 -19,131	-57%	-$788K	0.02%	349
2025 Q2	$1.11M	Buy	+33,636	New	+$1.17M	0.03%	332
2024 Q1	–	Sell	-8,095	Closed	-$676K	–	431
2023 Q4	$676K	Sell	8,095 -52,194	-87%	-$1.89M	0.03%	255
2023 Q3	$1.78M	Sell	60,289 -2,387	-4%	-$79.5K	0.06%	209
2023 Q2	$2.04M	Sell	62,676 -42,913	-41%	-$1.59M	0.07%	207
2023 Q1	$3.72M	Buy	+105,589	New	+$4.31M	0.15%	169

Other funds holding CYTK

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

J. Goldman & Co's CYTK Position: Q2 2026 in Review

J. Goldman & Co increased its Cytokinetics (CYTK) stake by 50% in Q2 2026, buying an estimated $430K and bringing the position to 18,002 shares worth $1.53M. The position accounts for 0.04% of the portfolio, ranked #392.

J. Goldman & Co first reported a position in CYTK in Q1 2023 and has held it in 9 quarters since. The position peaked at $3.72M in Q1 2023. 482 funds tracked by Wall St. Rank hold CYTK as of Q2 2026.

J. Goldman & Co held 18,002 shares of Cytokinetics worth $1.53M as of Q2 2026.
J. Goldman & Co bought 5,995 Cytokinetics shares in Q2 2026, an estimated $430K.
Cytokinetics made up 0.04% of J. Goldman & Co's portfolio in Q2 2026, its #392 holding.
J. Goldman & Co first reported a position in Cytokinetics in Q1 2023 and has held it in 9 quarters since.
J. Goldman & Co's Cytokinetics position peaked at $3.72M in Q1 2023.
482 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2026.

Based on J. Goldman & Co's 13F filing for Q2 2026, filed 14 Aug 2026.